Compare Procter & Gamble Health with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs GSK PHARMA - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH GSK PHARMA PROCTER & GAMBLE HEALTH/
GSK PHARMA
 
P/E (TTM) x 52.2 53.8 97.1% View Chart
P/BV x 4.7 11.3 41.8% View Chart
Dividend Yield % 10.0 1.4 717.1%  

Financials

 PROCTER & GAMBLE HEALTH   GSK PHARMA
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
GSK PHARMA
Mar-19
PROCTER & GAMBLE HEALTH/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs3,5493,595 98.7%   
Low Rs1,3011,253 103.9%   
Sales per share (Unadj.) Rs511.4184.7 277.0%  
Earnings per share (Unadj.) Rs61.326.3 233.1%  
Cash flow per share (Unadj.) Rs74.029.2 253.8%  
Dividends per share (Unadj.) Rs440.0020.00 2,200.0%  
Dividend yield (eoy) %18.10.8 2,199.0%  
Book value per share (Unadj.) Rs927.8126.3 734.5%  
Shares outstanding (eoy) m16.60169.40 9.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.713.1 36.1%   
Avg P/E ratio x39.692.2 42.9%  
P/CF ratio (eoy) x32.883.1 39.4%  
Price / Book Value ratio x2.619.2 13.6%  
Dividend payout %717.976.1 943.8%   
Avg Mkt Cap Rs m40,257410,626 9.8%   
No. of employees `0001.15.0 22.9%   
Total wages/salary Rs m1,3135,372 24.4%   
Avg. sales/employee Rs Th7,486.76,306.7 118.7%   
Avg. wages/employee Rs Th1,157.61,083.1 106.9%   
Avg. net profit/employee Rs Th897.2898.0 99.9%   
INCOME DATA
Net Sales Rs m8,49031,281 27.1%  
Other income Rs m2441,023 23.8%   
Total revenues Rs m8,73432,304 27.0%   
Gross profit Rs m1,4826,009 24.7%  
Depreciation Rs m211486 43.5%   
Interest Rs m06 0.0%   
Profit before tax Rs m1,5146,540 23.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m66287 22.9%   
Tax Rs m5632,373 23.7%   
Profit after tax Rs m1,0174,454 22.8%  
Gross profit margin %17.519.2 90.8%  
Effective tax rate %37.136.3 102.4%   
Net profit margin %12.014.2 84.2%  
BALANCE SHEET DATA
Current assets Rs m15,34320,061 76.5%   
Current liabilities Rs m1,96014,543 13.5%   
Net working cap to sales %157.617.6 893.6%  
Current ratio x7.81.4 567.4%  
Inventory Days Days4957 85.8%  
Debtors Days Days2814 202.3%  
Net fixed assets Rs m1,20914,343 8.4%   
Share capital Rs m1661,694 9.8%   
"Free" reserves Rs m15,23519,704 77.3%   
Net worth Rs m15,40121,398 72.0%   
Long term debt Rs m02 0.0%   
Total assets Rs m17,59539,113 45.0%  
Interest coverage xNM1,091.0-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.8 60.3%   
Return on assets %5.811.4 50.7%  
Return on equity %6.620.8 31.7%  
Return on capital %10.331.9 32.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,636534 306.4%   
Fx outflow Rs m4,3687,091 61.6%   
Net fx Rs m-2,732-6,557 41.7%   
CASH FLOW
From Operations Rs m-1,3043,994 -32.6%  
From Investments Rs m12,697-1,433 -885.8%  
From Financial Activity Rs m-301-3,584 8.4%  
Net Cashflow Rs m11,093-1,023 -1,084.1%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 51.8 50.7 102.2%  
Indian inst/Mut Fund % 18.2 10.2 178.4%  
FIIs % 1.0 23.8 4.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 15.4 189.0%  
Shareholders   28,591 102,036 28.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  

Compare PROCTER & GAMBLE HEALTH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 93 Points Higher; Oil & Gas and Realty Stocks Witness Buying(Closing)

Indian share markets traded on a volatile note throughout the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the oil & gas sector.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Oct 16, 2019 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 5-YR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS